Cytokinetics (CYTK) Equity Ratio (2016 - 2024)
Historic Equity Ratio for Cytokinetics (CYTK) over the last 15 years, with Q3 2024 value amounting to 0.01.
- Cytokinetics' Equity Ratio rose 9836.5% to 0.01 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.01, marking a year-over-year increase of 9836.5%. This contributed to the annual value of 0.47 for FY2023, which is 34076.3% down from last year.
- As of Q3 2024, Cytokinetics' Equity Ratio stood at 0.01, which was up 9836.5% from 0.07 recorded in Q2 2024.
- Cytokinetics' Equity Ratio's 5-year high stood at 0.32 during Q3 2020, with a 5-year trough of 0.59 in Q3 2023.
- Its 5-year average for Equity Ratio is 0.07, with a median of 0.01 in 2024.
- Per our database at Business Quant, Cytokinetics' Equity Ratio skyrocketed by 66284.41% in 2020 and then crashed by 389003.76% in 2023.
- Cytokinetics' Equity Ratio (Quarter) stood at 0.21 in 2020, then skyrocketed by 36.46% to 0.29 in 2021, then plummeted by 136.68% to 0.11 in 2022, then tumbled by 340.76% to 0.47 in 2023, then surged by 97.93% to 0.01 in 2024.
- Its Equity Ratio was 0.01 in Q3 2024, compared to 0.07 in Q2 2024 and 0.49 in Q1 2024.